Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Editor´s Picks
Chinese Trade Barriers Move into Trump's Focus(3/14/2018 )  (Premium)
China Prepares for Big Pharma(3/13/2018 )  (Premium)
The Market
China's Fibromyalgia Market Projected To Grow 18.7% CAGR Till 2022(3/15/2018 )  (free)
Industry News
HitGen and BASF Enter DNA-Encoded Library Based Research Collaboration(3/15/2018 )  (Premium)
United Biopharma Boosts China Presence with New Biologic Facility in Yangzhou(3/13/2018 )  (Premium)
Eisai Launches GI Prokinetic Agent Cidine in China(3/13/2018 )  (Premium)
Boehringer Launches IPF Drug Vargatef (nintedanib) in China(3/13/2018 )  (Premium)
Novo Nordisk Launches New Insulin Degludec Tresiba in China(3/13/2018 )  (Premium)
Hua Medicine Plans $400M Hong Kong IPO(3/13/2018 )  (Premium)
Regulatory News
CFDA Issues Pharmaceutical Research Guidance for Phase III Trials of Innovative Chemical Drugs(3/16/2018 )  (Premium)
CFDA Issues Technical Guidelines for Genotoxicity Study of Drugs(3/15/2018 )  (Premium)
CFDA Seeks Comments on Matters Related to Custom Clearance of APIs and Excipients(3/14/2018 )  (Premium)
China Reorganizes Drug Regulation in Gigantic Government Shakeup(3/13/2018 )  (Premium)
CDE Solicits Comments for Proposed Technical Guidance Documents(3/13/2018 )  (Premium)
CDE Seeks Feedbacks on Draft Rules for of Drug R&D and Evaluation Communication(3/12/2018 )  (Premium)
General Health
The New Boss on the Block: State Medical Insurance Administration (SMIA)(3/16/2018 )  (Premium)
China Reshuffles Central Government, Overhauling Healthcare, BMI and Drug Regulation(3/13/2018 )  (Premium)
Product/R&D News
CMBG Announces Positive 48-Week Data of AlloJoin haMPC Knee Osteoarthritis China Phase I Trial(3/16/2018 )  (free)
Chi-Med On Its Way for First Drug Approval in China This Year(3/13/2018 )  (Premium)
API/Bulk Drug News
Stada: Pollution Crackdown in China Led to Pharma Supply Challenges(3/13/2018 )  (Premium)
People in the News
Recent Official and Executive Moves(3/15/2018 )  (Premium)
Recent Executive Moves(3/12/2018 )  (Premium)
Other News
Upcoming Event: International Conferences on Medical & Surgical Nursing(3/12/2018 )  (free)
Upcoming Event: 5th Annual PharmaCon Asia(3/12/2018 )  (free)
Upcoming Event: ISPE Singapore Conference and Exhibition 2018(3/12/2018 )  (free)
Upcoming Event: Biopharma Development and Production Week(3/12/2018 )  (free)
Upcoming Event: 4th Annual Asia Healthcare Summit(3/12/2018 )  (free)
Upcoming Event: International conference on Pulmonary Medicine and Respiratory Diseases(3/12/2018 )  (free)
© Wicon International GroupˇˇSupport by: www.heightow.com Home | Site map | Contact Us | Links